Ekso Bionics Stock Price, News & Analysis

Ekso Bionics (Nasdaq: EKSO) announced its Q3 financial results for 2020, reporting revenues of $2.9 million, a sequential increase from $2.3 million in Q2. Gross margins improved to 63% versus 53% a year earlier, attributed to higher selling prices and reduced production costs. Cash reserves stood at $14.5 million, bolstered by $2.5 million from warrant exercises. However, overall revenue decreased compared to last year due to COVID-19 impacts on sales. Despite challenges, the company launched the EVO exoskeleton, which received positive initial interest.

Ekso Bionics (Nasdaq: EKSO) has launched its innovative EVO exoskeleton, aimed at reducing fatigue-related injuries among industrial workers. EGM Builders is the first customer to adopt this technology, which offers lift assistance to alleviate physical strain during overhead tasks. The EVO device enhances worker safety and productivity, aligning with EGM Builders' commitment to employee well-being. Despite the promising features, the company faces potential risks, including market acceptance and competition, as indicated in their forward-looking statements.

Ekso Bionics announced it will release its third quarter 2020 financial results on October 29, 2020, after trading hours. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss the outcomes and recent developments. Interested investors can join by calling 877-407-3036 (domestic) or 201-378-4919 (international), and a live webcast will be accessible on the company's website. A replay of the call will be available for two weeks post-event.

Ekso Bionics Holdings (Nasdaq: EKSO), a leader in exoskeleton technology, announced that CFO Jack Glenn will present at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference on September 16, 2020, at 11:30 am ET. The presentation will highlight the company's advancements in exoskeleton solutions, aimed at enhancing human strength and mobility in various applications. A live and archived webcast will be available on the company's investor website.

Ekso Bionics reported financial results for Q2 2020, revealing revenue of $2.3 million, up from $1.5 million in Q1 but down from $3.3 million in Q2 2019. The company achieved a record gross margin of 56%, up from 48% year-over-year. Despite revenue growth from the previous quarter, a loss of $11.8 million was recorded, compared to $3.1 million in 2019. The firm raised $11.1 million in financing and received FDA clearance for its EksoNR robotic exoskeleton, expanding its market potential. However, revenue decline was attributed to COVID-19 impacts.

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) announced that it will release its financial results for Q2 2020 on July 30, 2020, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and recent company developments. Investors can listen by dialing 877-407-3036 or via a live webcast on the company’s website. A replay will be available for two weeks. Ekso Bionics is a leader in exoskeleton technology, focusing on medical and industrial applications, and aims to enhance human mobility and endurance.

Ekso Bionics (Nasdaq: EKSO) announced FDA 501(k) clearance for its EksoNR robotic exoskeleton for rehabilitation in patients with acquired brain injury (ABI). This marks the first exoskeleton approved for ABI rehabilitation, expanding its applications beyond stroke and spinal cord injury. The company highlights the estimated 3.7 million annual incidences of TBI and stroke in the U.S., potentially increasing patient accessibility to the technology. The EksoNR is already in use at over 270 rehabilitation centers globally, aiming to enhance recovery outcomes.

Ekso Bionics Holdings (Nasdaq: EKSO) has completed a registered direct offering of 1,747,704 shares at $4.5145 each, raising approximately $7.89 million in gross proceeds. Additionally, the company issued warrants for up to 873,852 shares at an exercise price of $5.18, with a term of 5.5 years. Proceeds will be allocated for working capital and general corporate purposes. The offering complies with Nasdaq rules and was facilitated by H.C. Wainwright & Co.

Ekso Bionics Holdings (Nasdaq: EKSO) announced that the Committee on Foreign Investment in the U.S. (CFIUS) has raised national security concerns regarding their joint venture with Zhejiang Youchuang Venture Capital Investment Co. The CFIUS has issued a National Security Agreement, requiring the termination of Ekso's role in the venture. Established in 2019, the joint venture aimed to develop the exoskeleton market in Asia. CEO Jack Peurach expressed disappointment but affirmed the termination will not significantly impact 2020 operations.